Reil, J.-C. et al. Aldosterone promotes atrial fibrillation. Eur. Heart J. 33, 2098–2108 (2012).

Article  CAS  PubMed  Google Scholar 

Crompton, M., Skinner, L. J., Satchell, S. C. & Butler, M. J. Aldosterone: essential for life but damaging to the vascular endothelium. Biomolecules 13, 1004 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monticone, S. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41–50 (2018).

Article  CAS  PubMed  Google Scholar 

Rossi, G. P., Seccia, T. M., Maiolino, G. & Cesari, M. The cardiovascular consequences of hyperaldosteronism. Ann. Endocrinol. 82, 174–178 (2021).

Article  Google Scholar 

Brown, N. J. Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens. 14, 235–241 (2005).

Article  CAS  PubMed  Google Scholar 

Verma, S. et al. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am. J. Physiol. Heart Circ. Physiol. 326, H670–H688 (2024).

Article  CAS  PubMed  Google Scholar 

Briet, M. et al. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension 67, 897–905 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levy, D. G., Rocha, R. & Funder, J. W. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 89, 2736–2740 (2004).

Article  CAS  PubMed  Google Scholar 

Rossi, G. P., Rossi, F. B., Guarnieri, C., Rossitto, G. & Seccia, T. M. Clinical management of primary aldosteronism: an update. Hypertension 81, 1845–1856 (2024).

Article  CAS  PubMed  Google Scholar 

Rossi, G. P. et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 93, 2566–2571 (2008).

Article  CAS  PubMed  Google Scholar 

Malendowicz, L. K. et al. Effects of leptin and leptin fragments on steroid secretion of freshly dispersed rat adrenocortical cells. J. Steroid Biochem. Mol. Biol. 87, 265–268 (2003).

Article  CAS  PubMed  Google Scholar 

Huby, A. C. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132, 2134–2145 (2015).

Article  CAS  PubMed  Google Scholar 

Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243–1248 (2005).

Article  CAS  PubMed  Google Scholar 

Seccia, T. M. et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J. Hypertens. 38, 332–339 (2020).

Article  CAS  PubMed  Google Scholar 

Seccia, T. M., Caroccia, B., Muiesan, M. L. & Rossi, G. P. Atrial fibrillation and arterial hypertension: a common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. Int. J. Cardiol. 206, 71–76 (2016).

Article  PubMed  Google Scholar 

Reincke, M. et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension 60, 618–624 (2012).

Article  CAS  PubMed  Google Scholar 

Wu, V. C. et al. Long term outcome of Aldosteronism after target treatments. Sci. Rep. 6, 32103 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Douma, S. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371, 1921–1926 (2008).

Article  CAS  PubMed  Google Scholar 

Poulter, N. R., Prabhakaran, D. & Caulfield, M. Hypertension. Lancet 386, 801–812 (2015).

Article  PubMed  Google Scholar 

McEvoy, J. W. et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur. Heart J. 45, 3912–4018 (2024).

Article  PubMed  Google Scholar 

Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059–2068 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishizaka, M. K., Zaman, M. A. & Calhoun, D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16, 925–930 (2003).

Article  CAS  PubMed  Google Scholar 

Calhoun, D. A. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J. Clin. Hypertens. 9, 19–24 (2007).

Article  CAS  Google Scholar 

Chapman, N. et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49, 839–845 (2007).

Article  CAS  PubMed  Google Scholar 

Torresan, F. et al. Resolution of drug-resistant hypertension by adrenal vein sampling-guided adrenalectomy: a proof-of-concept study. Clin. Sci. 134, 1265–1278 (2020).

Article  Google Scholar 

Rossi, G. P., Battistel, M., Seccia, T. M., Rossi, F. B. & Rossitto, G. Subtyping of primary aldosteronism by adrenal venous sampling. Endocr. Rev. 46, 501–517 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turcu, A. F. et al. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J. Am. Heart Assoc. 11, e025952 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Rossi, G. P. et al. A Prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293–2300 (2006).

Article  CAS  PubMed  Google Scholar 

Weber, K. T. et al. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr. Drug. Targets 4, 505–516 (2003).

Article  CAS  PubMed  Google Scholar 

Brunner, H. R. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286, 441–449 (1972).

Article  CAS  PubMed  Google Scholar 

Alderman, M. H., Sealey, J. E. & Laragh, J. H. Plasma renin activity and ischemic heart disease. N. Engl. J. Med. 330, 506–507 (1994).

Article  CAS  PubMed  Google Scholar 

Rossi, G. P. et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27, 1039–1045 (1996).

Article  CAS  PubMed